about the author

ENDPOINTS

editor@endpointsnews.com

author articles

As­traZeneca's prized Imfinzi/treme­li­mum­ab com­bo fails again — this time in head and neck can­cer

7 years ago
R&D

Mallinck­rodt to spin off gener­ics busi­ness; Be­yond­Spring ready to sub­mit ap­proval for lead drug in Chi­na

7 years ago
News Briefing

In search of biotech hub glo­ry, the Big Ap­ple lures lo­cal star­tups with lab space

7 years ago
Pharma

Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

7 years ago
R&D

While we wait for NASH da­ta, Gen­fit re­ports pos­i­tive elafi­bra­nor da­ta in PBC pa­tients

7 years ago
R&D

UK sets up vac­cines cen­tre as Brex­it looms; Shang­hai's Elpi­science bags $35M in Se­ries B

7 years ago
News Briefing

A last-ditch ef­fort to de­rail Take­da’s $62B Shire buy­out goes down in flames

7 years ago
Deals
Pharma

Gilead­'s HIV drug De­scovy wins Chi­na's en­dorse­ment; Re­vance in­vestors smile as frown lines drug suc­ceeds piv­otal ...

7 years ago
News Briefing

Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

7 years ago
R&D

No­var­tis plots to re­tain hives pa­tients with mon­o­clon­al an­ti­body that out­shines Xo­lair

7 years ago
R&D

Armed with up­dat­ed 24-week PhI­II da­ta, GBT con­vinces FDA to re­view sick­le cell drug un­der ac­cel­er­at­ed path­way

7 years ago
R&D

Red­Hill's an­tibi­ot­ic Tal­i­cia edges clos­er to ap­proval, af­ter sec­ond suc­cess­ful Phase III study

7 years ago
R&D

Fi­nal­ly sat­is­fied with Oc­u­lar's man­u­fac­tur­ing set­up, FDA ap­proves eye drug/de­vice Dex­ten­za

7 years ago
Pharma

Spot­light on drug pric­ing could be cat­a­lyst for change in US biosim­i­lar land­scape

7 years ago
R&D
Pharma

Lund­beck­'s Dun­sire has some­thing to cheer as Rex­ul­ti com­bo shows promise in PTSD

7 years ago
R&D

Boehringer ax­es biosim­i­lar de­vel­op­ment out­side US; Macro­Gen­ics, Chi­na's Zai Labs join forces to de­vel­op I/O ...

7 years ago
News Briefing

Cat­a­lyst Phar­ma's LEMS drug Fir­dapse wins FDA nod, as reg­u­la­tors keep the ap­proval en­gine run­ning at record speed

7 years ago
Pharma

In­cyte hires Janssen ex­ec as CSO Hu­ber moves to Third Rock; Syn­thorx set terms for $100M IPO

7 years ago
News Briefing

Found­ed by for­mer Phar­mas­set, Idenix ex­ecs, hep B com­pa­ny An­tios nabs $25M Se­ries A

7 years ago
Financing

Bio­Haven hopes to soothe Chi­nese headaches with Shang­hai sub­sidiary

7 years ago
China

BeiGene inks $60M li­cens­ing, re­search pacts with Zymeworks; Mer­ck, Ab­b­Vie, Am­gen back neu­ro up­start

7 years ago
News Briefing

In the lat­est re­verse merg­er, Vi­en­na's Ar­sa­nis serves as ve­hi­cle for X4 Phar­ma's Nas­daq list­ing

7 years ago
Pharma

Trump pro­pos­al ta­pers Medicare pro­tec­tion for cer­tain drugs if drug­mak­ers don't tem­per pric­ing

7 years ago
Pharma

Af­ter falling off a cliff, Edge Ther­a­peu­tics pro­vides can­cer-fo­cused PDS Biotech a re­verse merg­er on­to Nas­daq

7 years ago
Pharma
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times